Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: maize starch; magnesium stearate; silicified microcrystalline cellulose; croscarmellose sodium - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 100 mg - tablet - excipient ingredients: croscarmellose sodium; magnesium stearate; silicified microcrystalline cellulose; maize starch - flecar is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecar should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecar tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate - flec-em is indicated for:,1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes b) due to dual av nodal pathways in patients with debilitating symptoms c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flec-em may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flec-em should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flec-em in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs. flec-em tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

emcure pharmaceuticals pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate - flec-em is indicated for:,1. supraventricular arrhythmias: a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes b) due to dual av nodal pathways in patients with debilitating symptoms c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flec-em may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flec-em should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flec-em in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs. flec-em tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous (available in other brands) therapy or conversion by other means.

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose

Canada - engelsk - Health Canada

apotex inc - flecainide acetate - tablet - 50mg - flecainide acetate 50mg - class ic antiarrythmics

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium

Irland - engelsk - HPRA (Health Products Regulatory Authority)

teva b.v. - flecainide acetate - tablet - 100 milligram(s) - antiarrhythmics, class ic; flecainide

Irland - engelsk - HPRA (Health Products Regulatory Authority)

teva b.v. - flecainide acetate - tablet - 50 milligram(s) - antiarrhythmics, class ic; flecainide

USA - engelsk - NLM (National Library of Medicine)

a-s medication solutions - flecainide acetate (unii: m8u465q1wq) (flecainide - unii:k94fts1806) - in patients without structural heart disease, flecainide acetate is indicated for the prevention of: flecainide acetate is also indicated for the prevention of: use of flecainide acetate for the treatment of sustained vt, like other antiarrhythmics, should be initiated in the hospital. the use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. because of the proarrhythmic effects of flecainide acetate tablets, usp, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. flecainide acetate should not be used in patients with recent myocardial infarction. (see boxed warnings.) use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended. (see boxed warnings.) as is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival